This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Status:
Not yet recruiting

Trial end date:
2025-08-31

Target enrollment:

Participant gender:

The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.

Phase 3

Sinocelltech Ltd.

Ranibizumab